

**Participant No.**

**HIT EXERCISE:  
Heparin Induced Thrombocytopenia (HIT) Screening**

**July 2023**

Please find enclosed two samples labelled for HIT screening. On receipt, the samples should be stored at or below 4°C until testing.

Samples **HIT23:03 & HIT23:04** should be reconstituted by carefully adding exactly **0.5 ml** of distilled water to the vial, mixed gently and left standing at room temperature for 10 minutes before testing.

All samples should be tested using your routine HIT screening method. Method details and results should be entered overleaf.

*Clinical Details:*

Sample HIT23:03 is a referral sample for HIT assay performed at your centre. The clinical details include patient was on unfractionated heparin for 3 days and platelet count has been dropping.

Sample HIT23:04 is a sample for HIT assay performed at your centre. The clinical details include patient was on unfractionated heparin for 3 days and platelet count has been dropping.

**Please return this sheet by email ([neqas@coageqa.org.uk](mailto:neqas@coageqa.org.uk)) by the closing date of 1<sup>st</sup> September 2023.**

**Note performance assessment will be by method group and interpretations for samples HIT23:03 and HIT23:04.**

**Please note, if you use more than one method to investigate HIT, please give details and results for each method.**

**Important note.** These samples have been screened for hepatitis B surface antigen (HBsAg) and for antibodies to human immunodeficiency virus types 1 & 2 (anti-HIV-1+2), and hepatitis C which were not detected. Samples will also be tested for covid 19 RNA. However, normal precautions should be taken in their handling and disposal.

**Participant No.**

**Method – Please indicate your method below, and antibody specificity in question 2.**

Method	Please tick	Method	Please tick
AESKULISA HiT ii		Stago STIC Expert	
Biotec Milenia Quickline HIT		Werfen Acustar AntiPF4 heparin	
Hyphen Zymutest HIA		Werfen HIT-ab (PF4-H)	
Lifecodes Immucor PF4		Other ( <i>Please give details below</i> )	
Stago Asserachrom HPIA			
Other kit details			

**2. HIT antibody detection – IgG or G/A/M**

(please tick) Ig G/A/M ☐ Ig G only ☐

**3. RESULTS REPORTED AS:**

Qualitative (Pos/Neg) ☐ Quantitative (OD) ☐  
 % of positive control ☐ Other ☐

**4. CUT-OFFS/REFERENCE RANGE**

- a) What cut-off point do you employ for the test? .....
- b) Is this determined in your centre? Yes ☐ No ☐
- c) Is this determined for each new batch/lot of reagent? Yes ☐ No ☐

**5. CONTROLS: Do you use a positive control plasma when performing HIT screening? (if yes, please state source)**

No ☐ Yes ☐ (please give details) .....

**6. Result (please indicate units if applicable):**

Sample	Result	Interpretation
HIT23:03		
HIT23:04		

**7. Comments:**

.....  
 .....  
 .....  
 .....  
 .....

**Please return this sheet by email ([negas@coagega.org.uk](mailto:negas@coagega.org.uk)) by the closing date of 1<sup>st</sup> September 2023.**